P2.06-017 Amethyst NSCLC Trial: Phase 2 Study of MGCD265 in Patients with Advanced or Metastatic NSCLC with Activating Genetic Alterations in MET
Year: 2017
Type: article
Source: Journal of Thoracic Oncology
Authors: Lyudmila Bazhenova, Dong-Wan Kim, Luigi Cavanna, Ji-Youn Han, Jong Seok Lee, Hoon-Kyo Kim, Byoung Chul Cho, Marshall Schreeder, Ashiq Masood, Igor Rybkin, Melissa Johnson, Britt Boleman, Marta Batus, Estelamari Rodriguez, David Hong, Pasi Jänne, Raul Mena, Frederico Cappuzzo, Ivor Percent, Vanessa Tassell, James Christensen, Demiana Faltaos, Richard Chao, Hirak Der-Torossian, Diane Potvin, Ranee Mehra
Institutions: University of California San Diego, Seoul National University Hospital, Azienda Unità Sanitaria Locale Piacenza, Guglielmo da Saliceto Hospital, National Cancer Center, Seoul National University Bundang Hospital, The Catholic University of Korea St. Vincent's Hospital, Catholic University of Korea, Yonsei University, Yonsei University Health System, Yonsei Cancer Hospital, Clearview Cancer Institute, Washington University in St. Louis, Henry Ford Health, Sarah Cannon, Prisma Health, Rush University Medical Center, Mount Sinai Medical Center, The University of Texas MD Anderson Cancer Center, Dana-Farber Cancer Institute, Providence Saint Joseph Medical Center, Mirati Therapeutics (United States), Fox Chase Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2569017572